Do Not Prescribe (DNP), Red
Decision Date:
March 2020



  • NICE TA665 - treatment of severe active rheumatoid arthritis. (Decision date - January 2021)
  • NICE TA744 - For moderate rheumatoid arthritis. (Decision date - December 2021)
  • NICE TA768 - Treatment of active psoriatic arthritis in adults who have responded inadequately to, or who are intolerant to ≥1 DMARDs. Upadacitinib may be used as monotherapy or in combination with methotrexate. (Decision date - March 2022)
  • NICE TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitisAdults commissioned by ICS. Adolescents commissioned by NHSE. (Decision date - September 2022)
  • NICE TA829 - Upadacitinib for treating active ankylosing spondylitis. ICB commissioned. (Decision date - November 2022)
  • NICE TA856 - Upadacitinib for treating moderately to severely active ulcerative colitis. ICB commissioned. (Decision date - February 2023)
  • NICE TA861 - For active non-radiographic axial spondyloarthritis. ICB commissioned. (Decision date - March 2023)
  • NICE TA905 - For previously treated moderately to severely active Crohn’s disease. ICB commissioned. (Decision date - June 2023)


  • Treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Await national guidance. (Decision date - April 2021) 
  • Moderate-to-severe Crohn's disease. Await national guidance. (Decision date - February 2022) 

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app